My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 485 / DOI: 10.3332/ecancer.2014.485

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Keywords: Drug repurposing, cimetidine, immunostimulant, ReDO project

Loading Article Metrics ... Please wait

Related articles

Review: Targeted therapies and immunotherapy in non-small-cell lung cancer

Abstract | Full Article | PDF Published: 23 Jun 2016 / DOI: 10.3332/ecancer.2016.648

Case Report: Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)?

Abstract | Full Article | PDF Published: 07 Jun 2016 / DOI: 10.3332/ecancer.2016.646

Case Report: Pulmonary metastasis as sole manifestation of relapse in previously treated localised prostate cancer: three exceptional case reports

Abstract | Full Article | PDF Published: 07 Jun 2016 / DOI: 10.3332/ecancer.2016.645

Conference Report: Highlights from the Tenth European Breast Cancer Conference (EBCC10), Amsterdam, 9–11 March 2016

Abstract | Full Article | PDF Published: 03 Jun 2016 / DOI: 10.3332/ecancer.2016.644

Case Report: Successful palliative approach with high-intensity focused ultrasound in a patient with metastatic anaplastic pancreatic carcinoma: a case report

Abstract | Full Article | PDF Published: 21 Apr 2016 / DOI: 10.3332/ecancer.2016.635



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence